title: [Intravitreal treatment of patients with branch retinal vein occlusion depending on the duration of macular edema].
abstract: OBJECTIVE
  The aim of this study was to evaluate the effects of intravitreal treatment with bevacizumab (IVB) compared with triamcinolone (IVT) in patients with macular edema due to branch retinal vein occlusion (BRVO) depending on the duration of BRVO.
  
  
  METHODS
  A total of 65 BRVO patients were divided into 2 subgroups: group 1 with early treatment (≤ 3 months since onset of BRVO) and group 2 with late treatment (> 3 months since onset). For the two groups IVB was injected into 17 eyes as early (IVB1) and into 18 eyes as late (IVB2) treatment. For comparison IVT was injected into 14 eyes as early (IVT1) and into 16 eyes as late (IVT2) treatment. Best corrected visual acuity (BCVA) and central retinal thickness (CRT) were analyzed at baseline, 1, 3 and 6 months after treatment.
  
  
  RESULTS
  In both subgroups a significant improvement of BCVA and CRwas observed. After 6 months, for patients with early treatment, IVB1 showed better results than IVT1 (BCVA: p = 0.008, CRT: p = 0.021). In the late treatment no significant differences between IVT2 and IVB2 were found.
  
  
  CONCLUSIONS
  Bevacizumab and triamcinolone significantly improved BCVA and CRT in patients with BRVO. The best BCVA was found if bevacizumab was used as early treatment. In the late treatment no significant differences between bevacizumab and triamcinolone were observed.
authors.affiliation: Klinik und Poliklinik für Augenheilkunde, Universität Leipzig, Liebigstr. 10-14, 04103, Leipzig, Deutschland, matus.rehak@medizin.uni-leipzig.de.
authors.forename: M
authors.initials: M
authors.lastname: Rehak
authors.forename: E
authors.initials: E
authors.lastname: Spies
authors.forename: M
authors.initials: M
authors.lastname: Scholz
authors.forename: P
authors.initials: P
authors.lastname: Wiedemann
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology*; D008297:Male; D012170:Retinal Vein Occlusion / Q000150:complications* / Q000188:drug therapy*; D014221:Triamcinolone / Q000008:administration & dosage*; D014786:Vision Disorders / Q000209:etiology / Q000517:prevention & control*; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D014221:Triamcinolone; D000068258:Bevacizumab